Download PDF
Nuklearmedizin 1970; 09(03): 248-258
DOI: 10.1055/s-0038-1624714
Originalarbeiten — Original Articles — Travaux Originaux
Schattauer GmbH

Whole-Body and Renal Clearance of 203Hg-Chlormerodrin. The Effect of Chelating Agents on Clearance

L’élimination corporelle et rénale de la 203Hg-chlormérodrine et l’influence des chélateursGanzkörper- und Nieren-Clearance von 203Hg-Chlormerodrin und die Wirkung von Chelatoren
G. T. Krishnamurthy   *   1
1   From the Nuclear Medicine Service, Wadsworth Hospital, Veterans Administration Center, Los Angeles, Calif., the Department of Medicine, University of California School of Medicine, Los Angeles, and the School of Pharmacy, University of Southern California, Los Angeles, Calif.
,
Marianne Lederer   1
1   From the Nuclear Medicine Service, Wadsworth Hospital, Veterans Administration Center, Los Angeles, Calif., the Department of Medicine, University of California School of Medicine, Los Angeles, and the School of Pharmacy, University of Southern California, Los Angeles, Calif.
,
Manuel Tubis   1
1   From the Nuclear Medicine Service, Wadsworth Hospital, Veterans Administration Center, Los Angeles, Calif., the Department of Medicine, University of California School of Medicine, Los Angeles, and the School of Pharmacy, University of Southern California, Los Angeles, Calif.
,
William H. Blahd   1
1   From the Nuclear Medicine Service, Wadsworth Hospital, Veterans Administration Center, Los Angeles, Calif., the Department of Medicine, University of California School of Medicine, Los Angeles, and the School of Pharmacy, University of Southern California, Los Angeles, Calif.
› Author Affiliations
Further Information

Publication History

Received: 03 March 1970

Publication Date:
23 January 2018 (online)

    Permissions and Reprints

Summary

Using a whole-body counter, normal whole-body and renal clearances of 203Hg-chlormerodrin and the action of L-cysteine and D-penicillamine as chelating agents have been studied in 19 subjects.

L-cysteine and D-penicillamine given in varying doses at different time intervals did not change the whole-body or renal retention of mercury. This indicates that these chelating agents are not effective when mercury is present in the body in minute quantities. The search for better and more convenient renal scanning agents should continue, as should also the search for a better chelating agent to enhance clearance of 203Hg from the body.

L’élimination normale corporelle et rénale de la 203Hg-chlormérodrine et l’action de la L-cystéine et de la D-penicillamine comme chélateurs ont été étudiés chez 19 sujets avec un anthropogammamètre.

La L-cystéine et la D-pénicillamine administrées à des doses variées et à des intervalles de temps différents ne changèrent pas la rétention corporelle ou rénale du mercure. Ce résultat indique que ces chélateurs ne sont pas efficaces lorsque le mercure est présent dans le corps en quantités infimes. La recherche pour un composé meilleur et plus commode pour la scintigraphic rénale doit continuer, de même que la recherche pour un meilleur chélateur pour éliminer le 203Hg du corps.

19 Personen ohne Nierenerkrankungen wurden in einem Ganzkörperzähler nach Verabreichung von 203Hg-chlormerodrin zur Bestimmung der Ganzkörper-und der direkten renalen Clearance gemessen und die chelierende Wirkung von L-Cysteine und D-Penicillamine untersucht.

Weder L-Cysteine noch D-Penicillamine, in verschiedenen Mengen und Zeitabständen verabreicht, veränderten die Ganzkörperoder die Nieren-Retention des Quecksilbers. Diese Chelate sind anscheinend unwirksam, wenn Quecksilber in nur sehr geringen Mengen im Körper vorhanden ist. Die Forschung nach wirkungsvolleren Verbindungen zur Nierenszintigraphie und nach besseren Chelatoren sollte weiter fortgesetzt werden, um die Ausscheidung des 203Hg zu beschleunigen.

1 G. T. Krishnamurthy, M.B.B.S., Fellow in Nuclear Medicine, Veterans Administration Center, Los Angeles, Calif.


2 Marianne Lederer, B.S., Nuclear Medicine Service, Veterans Administration Center, Los Angeles, Calif.


3 Manuel Tubis, Ph. D., Research Biochemist, Nucleár Medicine Service, Veterans Administration Center, Los Angeles, and Visiting Associate Professor of Pharmaceutical Chemistry, School of Pharmacy, University of Southern California, Los Angeles, Calif.


4 William, H. Blahd, M.D., Chief, Nuclear Medicine Service, Veterans Administration Center, Los Angeles, and Professor of Medicine, Department of Medicine, University of California, Los Angeles, Calif.


* Correspondence: G. T. Krishnamurthy, M.B.B.S., Nuclear Medicine Service D-101, Wadsworth Hospital Veterans Administration Center, Los Angeles, California 90073.


 

  • References

  • 1 Benesch R, Benesch R. E. Reaction of thiols with organic mercury compounds. Arch. Biochem. Biophys 1952; 38: 425-441.
    CrossrefPubMedGoogle Scholar
  • 2 Blau M, Bender M. A. Radiomercury (203Hg) labeled neohydrin: A new agent for brain tumor localization. J. nucl. Med 1962; 3: 83-93.
    Google Scholar
  • 3 Boulding J. E, Baker D. A. The treatment of metal poisoning with penicillamine. (Preliminary communication). Lancet ii 1957; 985.
    Google Scholar
  • 4 Boyd P. R, Walker G, Henderson I. N. The treatment of tetraethyl lead poisoning. Lancet i 1957: 181-185.
    Google Scholar
  • 5 Brown C. N. Hepatolenticular degeneration. Brit. Med. J. ii 1959; (correspondence) 528.
    Google Scholar
  • 6 Cardinale A, De Simone G. F. The use of sulfhydryl containing drugs and chelating agents to reduce renal irradiation during 203Hg chlormerodrin scintigraphy. J. nucl. Biol. Med 1968; 12: 121-127.
    PubMedGoogle Scholar
  • 7 Farah A, Kruse R. The relation of mercurial diuresis to cellular protein-bound sulfhydryl changes in renal cells. J. Pharm, exp. Therap 1960; 130: 13-19.
    Google Scholar
  • 8 Goodman L. S, Gillman A. Z. The Pharmacological Basis of Therapeutics; A Textbook of Pharmacology, Toxicology and Therapeutics for Physicians and Medical Students. 1965; 832.
    PubMedGoogle Scholar
  • 9 Lawrie N. R, Carter R. A. Acute case of Wilson’s disease (hepatolenticular degeneration). Lancet i 1958; 1309-1311.
    PubMedGoogle Scholar
  • 10 McAfee J. C, Wagner Jr. H. N. Visualization of renal parenchyma by scintiscanning with 203Hg neohydrin. Radiology 1960; 75: 820-821.
    CrossrefPubMedGoogle Scholar
  • 11 Miller H. C, Green J. P, Le vine J. Metabolism of chlormerodrin-203Hg. Invest. Urol. Is 1963; 112-120.
    Google Scholar
  • 12 Multhauf R. Medical Chemistry and “The Paracelsians”. Bull. Hist. Med 1954; 28: 122.
    Google Scholar
  • 13 Parameshvara V. Mercury poisoning and its treatment with N-acetyl-D, L-penicillamine. Brit. J. industr. Med 1967; 24: 73-76.
    PubMedGoogle Scholar
  • 14 Reba R. C, McAfee J. G, Wagner Jr. H. N. Radiomercury-labelled chlormerodrin for in vivo uptake studies and scintillation scanning of unilateral renal lesions associated with hypertension. Medicine (Bait.) 1963; 42: 269-296.
    CrossrefPubMedGoogle Scholar
  • 15 Smith A. D. M, Mille r J. W. Treatment of inorganic mercury poisoning with N acetyl-D, L-penicillamine. Lanceti 1961; 640-642.
    Google Scholar
  • 16 Sodee D. B. A new scanning isotope, mercury197. A preliminary report. J. nucl. Med 1963; 4: 335-344.
    PubMedGoogle Scholar
  • 17 Three foot S. A, Ray C. T, Burch G. E, Cronvich J. A, Milnor J. P, Overman W, Gordon W. Concentration-time course in the plasma of man of radiomercury introduced as a mercurial diuretic. J. clin. Invest 1949; 28: 661-670.
    CrossrefPubMedGoogle Scholar
  • 18 Vogl Alfred. The discovery of the organic mercurial diuretics. Amer. Heart J 1950; 39: 881-883.
    CrossrefPubMedGoogle Scholar
  • 19 Walshe J. M. Wilson’s disease; new oral therapy; preliminary communication. Lanceti 1956: 25-26.
    Google Scholar
  • 20 Walshe J. M. Penicillamine, a new oral therapy for Wilson’s disease. Amer. J. Med 1956; 21: 487-495.
    CrossrefPubMedGoogle Scholar
  • 21 Walshe J. M. Current views on the pathogenesis and treatment of Wilson’s disease. Arch. Intern. Med 1959; 103: 155-161.
    CrossrefPubMedGoogle Scholar